Braun Stacey Associates Inc Neurocrine Biosciences Inc Transaction History
Braun Stacey Associates Inc
- $2.82 Billion
- Q3 2025
A detailed history of Braun Stacey Associates Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Braun Stacey Associates Inc holds 183,027 shares of NBIX stock, worth $26.5 Million. This represents 0.91% of its overall portfolio holdings.
Number of Shares
183,027
Previous 170,370
7.43%
Holding current value
$26.5 Million
Previous $21.4 Million
19.99%
% of portfolio
0.91%
Previous 0.85%
Shares
8 transactions
Others Institutions Holding NBIX
# of Institutions
724Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...